CytoDyn Announces Cancer Update: 12-month Analysis of 28 mTNBC Patients Receiving Leronlimab Suggests an Increase of 3600% in 12-month OS in 75% of Patients with a Lower Level of Circulating Cells After Leronlimab Induction or at Baseline; 12-month PFS Continues at Near 600% Increase

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing